Investegate |Oncimmune Hldgs PLC Announcements | Oncimmune Hldgs PLC: Interim Results
Investegate announcements from Oncimmune Hldgs PLC, Interim Results
Source: investegate.co.uk
Genostics Company News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Genostics Company. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Genostics Company Today - Breaking & Trending Today
Oncimmune Holdings FY2021 revenues of £3.7 million (over 6x increase on FY2020)
Oncimmune Holdings FY2021 revenues of £3.7 million (over 6x increase on FY2020)
Source: directorstalkinterviews.com
Investegate |Oncimmune Hldngs PLC Announcements | Oncimmune Hldngs PLC: Full year results and progress update
Investegate announcements from Oncimmune Hldngs PLC, Full year results and progress update
Source: investegate.co.uk
.jpg)
Changes in Capital Market Preferences sees return of China IP Rights
Following termination of a partnership agreement with Genostics Company, the intellectual property and distribution rights for EarlyCDT® technology in the People’s Republic of China (PRC) and Hong Kong (HK), has returned to immunodiagnostics group Oncimmune Holdings, (Nottingham, UK). Click to read more...
Source: labmate-online.com
Oncimmune buys back EarlyCDT distribution rights for China | 5 May 2021
5 May 2021 | 09:25am StockMarketWire.com - Immunodiagnostics group Oncimmune said it had agreed to acquire the intellectual property and distribution rights for its lung-cancer diagnostics technology in China from Genostics Company. Oncimmune said the move would allow it to pursue an optimum route to market in an important territory. It had granted Genostics the exclusive rights to its EarlyCDT products. All material, IP, data, and goodwill would now be transferred back to Oncimmune, which would be be paid in full for royalties due in January 2021 under an existing technology licencing agreem...
Source: stockmarketwire.com